IndustryCompany release
Clearmind Medicine's psychedelic-derived PTSD compound patent application published in Hong Kong
Clearmind Medicine Inc. (CMND) · Thu 19 Nov 2026
Clearmind Medicine says a Hong Kong application covering psychedelic-derived compounds for PTSD and other mental health disorders has been published; no patent has yet been granted.
Clearmind Medicine (Nasdaq: CMND) announced on 19 November 2026 that a patent application filed in Hong Kong has been published. The application covers psychedelic-derived compounds intended for post-traumatic stress disorder (PTSD) and other mental health disorders.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Clearmind Medicine Inc. ↗
Article written by VigiEye from the official source (Clearmind Medicine Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Brainstorm Cell proposes governance reforms to settle NurOwn derivative suits, with $725,000 in fees
🇺🇸 Brainstorm Cell Therapeutics Inc. (BCLI) · Fri 20 Nov 2026
Scienture Q3 revenue reaches $1.25M as REZENOPY naloxone nasal spray launches
🇺🇸 Scienture Holdings, Inc. (SCNX) · Thu 19 Nov 2026
Medicus Pharma regains Nasdaq equity compliance after equity raise and debt-for-preferred swap
🇺🇸 Medicus Pharma Ltd. (MDCX) · Thu 19 Nov 2026
Kazia files FY2026 20-F, reporting A$61.2M cash and early paxalisib breast cancer data
Kazia Therapeutics Ltd (KZIA) · Thu 19 Nov 2026
Psyence Biomedical reports $1.94M half-year loss as equity line lifts cash to $21.1M
Psyence Biomedical Ltd. (PBM) · Thu 19 Nov 2026
Psyence Biomedical adds ibogaine for opioid use disorder via new Texas subsidiary
Psyence Biomedical Ltd. (PBM) · Thu 19 Nov 2026